Fig. 4.
Combination of oAD-IL7 and B7H3-CAR-T improved the anti-tumor effect in vivo. 2 × 105 GBM-LUCF cells were orthotopically injected into the NCG mice, and the bioluminescent imaging was performed twice a week since the 7th day after injection. The oncolytic virus was orthotopically injected on day 7, and the B7H3-CAR-T cells were systematically applied on day 9. a Experimental timeline for in vivo studies. b The representative bioluminescent images of the growth of glioblastoma over time were shown. c The expression of B7H3 and CXAR in the glioblastoma tissue of patient. Scale bar, 50 μm. d, e, and f Quantitated GBM-LUCF bioluminescence from each treatment group is displayed over time. g Average radiance of the three groups of the mice during the first 3 weeks. h Kaplan–Meier survival analysis of GBM-LUCF challenged mice after treatment with oncolytic virus and T cells. *P < 0.05; **P < 0.01; ***P < 0.001 (two-tailed paired t test). i H&E staining of the specimen removed from tumor-bearing mice that underwent a parallel experiment at day 30